RUNBEN BIOTECHNOLOGY (603193.SS)

CNY 35.7

(-0.31%)

EBITDA Summary of RUNBEN BIOTECHNOLOGY

  • RUNBEN BIOTECHNOLOGY's latest annual EBITDA in 2023 was 290.05 Million CNY , up 38.62% from previous year.
  • RUNBEN BIOTECHNOLOGY's latest quarterly EBITDA in 2024 Q3 was 93.59 Million CNY , down -46.58% from previous quarter.
  • RUNBEN BIOTECHNOLOGY reported an annual EBITDA of 209.27 Million CNY in 2022, up 34.47% from previous year.
  • RUNBEN BIOTECHNOLOGY reported an annual EBITDA of 152.69 Million CNY in 2021, up 25.43% from previous year.
  • RUNBEN BIOTECHNOLOGY reported a quarterly EBITDA of 161.28 Million CNY for 2024 Q2, up 286.58% from previous quarter.
  • RUNBEN BIOTECHNOLOGY reported a quarterly EBITDA of 43.22 Million CNY for 2024 Q1, down -11.64% from previous quarter.

Annual EBITDA Chart of RUNBEN BIOTECHNOLOGY (2023 - 2019)

Historical Annual EBITDA of RUNBEN BIOTECHNOLOGY (2023 - 2019)

Year EBITDA EBITDA Growth
2023 290.05 Million CNY 38.62%
2022 209.27 Million CNY 34.47%
2021 152.69 Million CNY 25.43%
2020 118.83 Million CNY 93.33%
2019 57.99 Million CNY 0.0%

Peer EBITDA Comparison of RUNBEN BIOTECHNOLOGY

Name EBITDA EBITDA Difference
Liuzhou Liangmianzhen Co., Ltd. 59.28 Million CNY -389.265%
Shanghai Jahwa United Co., Ltd. 864.85 Million CNY 66.463%
Henan Rebecca Hair Products Co., Ltd. 197.77 Million CNY -46.657%
Perfect Group Corp., Ltd 168.89 Million CNY -71.734%
Proya Cosmetics Co.,Ltd. 1.62 Billion CNY 82.155%
Lafang China Co.,Ltd 86.16 Million CNY -236.607%
Shanghai Flyco Electrical Appliance Co., Ltd. 1.38 Billion CNY 79.068%
Guangdong Marubi Biotechnology Co., Ltd. 354.54 Million CNY 18.191%
Hangzhou Haoyue Personal Care Co., Ltd 643.75 Million CNY 54.944%